文献速递耳科与耳神经

COVID-19药物治疗的安全性考量与耳毒性:叙述性综述

A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity.
PubMed 文献 · Laryngoscope · 2021-01-27

该叙述性综述通过检索ClinicalTrials.gov和PubMed数据库,总结了潜在COVID-19治疗药物的耳毒性证据。共识别出六种具有耳毒性副作用的药物,包括氯喹/羟氯喹、阿奇霉素、洛匹那韦-利托那韦、干扰素、利巴韦林和伊维菌素。结论认为停药可能改善或减轻耳毒性效应,建议对接受已知耳毒性药物治疗的患者(尤其老年和听力受损高危人群)考虑听力监测方案。

要点

  • 六种COVID-19候选治疗药物具有耳毒性副作用
  • 停药可能改善或减轻耳毒性效应
  • 识别听力损失、耳鸣或失衡/眩晕对早期干预至关重要

核心结论

  • 现有证据提示,停用耳毒性药物可能改善或减轻耳毒性效应。
  • 识别听力损失、耳鸣或失衡/眩晕对于促进早期干预和预防长期损害至关重要。
  • 医院应考虑对接受已知耳毒性COVID-19治疗药物的患者纳入听力监测方案,尤其是老年和听力受损等高危人群。

研究设计与样本

  • 叙述性综述,通过ClinicalTrials.gov和PubMed数据库检索COVID-19候选治疗药物,并针对每种药物在PubMed进行文献回顾以识别耳毒性相关文章。

主要发现

  • 共识别出六种具有耳毒性副作用的COVID-19候选治疗药物:氯喹和羟氯喹、阿奇霉素、洛匹那韦-利托那韦、干扰素、利巴韦林和伊维菌素。

临床怎么用

  • 临床应识别接受上述药物治疗患者的听力损失、耳鸣或失衡/眩晕症状,以便早期干预。
  • 对接受已知耳毒性药物治疗的患者,尤其老年和听力受损者,医院应考虑纳入听力监测方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE/HYPOTHESIS: The purpose of this review is to summarize evidence-based data regarding the ototoxic effects of potential COVID-19 therapeutics to treat patients suffering from SARS-CoV-2. METHODS: Medications under investigation as novel therapeutics to treat COVID-19 were identified using the search term coronavirus therapeutics, COVID therapeutics, and SARS-CoV-2 therapeutics on ClinicalTrials.gov and the PubMed Database. A literature review was performed using the PubMed Database for each proposed COVID-19 therapeutic to identify relevant articles. Search criteria included Medical Subject Headings (MeSH) and key word search terms for ototoxicity, vestibulotoxicity, hearing disorders, and vertigo. RESULTS: Six proposed COVID-19 therapeutics were identified as possessing ototoxic side effects including chloroquine and hydroxychloroquine, azithromycin, lopinavir-ritonavir, interferon, ribavirin, and ivermectin. CONCLUSIONS: Available evidence suggests that ototoxic effects may be improved or mitigated by stopping the offending agent. Recognition of hearing loss, tinnitus, or imbalance/vertigo is therefore crucial to facilitate early intervention and prevent long-term damage. Hospitals should consider the inclusion of audiologic monitoring protocols for patients receiving COVID-19 therapeutics with known ototoxicity, especially in high-risk patient groups such as the elderly and hearing impaired. Laryngoscope, 131:1626-1632, 2021.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Little C, Cosetti MK. A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity. Laryngoscope. 2021. PMID: 33491234. doi:10.1002/lary.29424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。